RAP-219 Phase 2 Mania Signal Is Real But Narrow — Phase 3 Design Will Decide Everything

Rapport's RAP-219 Achieves Phase 2 Win in Bipolar Mania

Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 in 253 adults with acute bipolar mania. The study met its primary endpoint, demonstrating a statistically significant 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale (YMRS) at three weeks (p=0.045). Patients treated with RAP-219 experienced a 15.4-point reduction in symptoms compared to 12.3 points for placebo. The drug also achieved its pre-specified secondary endpoint for overall mania severity and exhibited a favorable safety profile, with no severe treatment-emergent or serious adverse events. These results provide clinical proof-of-concept for RAP-219's novel mechanism in bipolar mania and support progression to Phase 3 trials, anticipated to begin in the second half of 2027. This marks RAP-219's second Phase 2 success, following positive data in drug-resistant focal epilepsy.

• RAP-219 achieved its primary endpoint in the Phase 2 trial for bipolar mania, showing a statistically significant 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale (YMRS) at three weeks (p=0.045). Patients receiving RAP-219 experienced a 15.4-point reduction in symptoms, while the placebo group saw a 12.3-point reduction. The drug also met its pre-specified secondary endpoint, demonstrating a statistically significant improvement in overall mania severity, reinforcing its therapeutic potential.
• The Phase 2 trial highlighted RAP-219's strong safety and tolerability, with no severe treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) reported. This is crucial for bipolar disorder treatment, where side effects often lead to discontinuation and relapse. Rapport's CEO emphasized that RAP-219's potential to offer a well-tolerated option could break the cycle of discontinuation, providing a differentiated profile compared to traditional neuroscience medications.
• RAP-219 operates via a novel TARPγ8-specific AMPA receptor negative allosteric modulator mechanism. This mechanism is hypothesized to offer a differentiated profile due to TARPγ8's minimal expression in the hindbrain, potentially reducing common adverse events. This positive readout in bipolar mania, following earlier Phase 2a success in drug-resistant focal epilepsy (reducing seizures by almost 78%), solidifies RAP-219's "pipeline-in-a-product" potential, positioning it for multi-blockbuster opportunities across significant market indications.

RAP-219's Phase 2 Efficacy and Safety in Bipolar Mania

A 2024 randomized clinical trial conducted at the Shanghai Mental Health Center compared Magnetic Seizure Therapy (MST) versus modified Electroconvulsive Therapy (ECT) in 48 patients with bipolar mania. The response rate was 95.0% (95% CI, 85.4%–100%) in the ECT group and 86.4% (95% CI, 72.1%–100%) in the MST group, with no statistically significant difference in YMRS reduction rate or response rate between groups. Notably, the time-by-group interaction was significant for the language domain (F1,24 = 7.17; P = .01), which was well preserved in patients receiving MST but worsened in those receiving ECT. No serious adverse effects were reported in either group, suggesting MST as a viable alternative with a more favorable cognitive safety profile.

A 2021 randomized, double-blind, controlled trial (ClinicalTrials.gov NCT00893581) compared lithium versus quetiapine over six weeks in 109 adolescents with acute manic or mixed episodes of early course bipolar I disorder. Quetiapine demonstrated a significantly greater reduction in YMRS score than lithium (−13.2 vs. −11.0; p < 0.001; effect size 0.39), with a response rate of 72% versus 49% (p = 0.012), though no differences in remission rates between groups were observed. Participants receiving quetiapine experienced more somnolence (p < 0.001), dizziness (p < 0.05), and weight gain (p < 0.05), while the most frequent side effects for lithium were headaches (60.8%), nausea (39.2%), somnolence (27.5%), and tremor (27.5%).

A 2024 retrospective, open-label, parallel-group comparative study examined intravenous valproic acid (IV-VPA) versus oral valproic acid (oral-VPA) in 100 inpatients with bipolar disorder experiencing a manic or depressive episode with concomitant symptoms of opposite polarity. Both formulations produced significant improvements across all psychometric scales (p < 0.001), including CGI, YMRS, MADRS, and HAM-A scores. However, the IV-VPA group exhibited superior efficacy, with significantly lower scores on all four scales at Day 3 and at discharge, along with higher response rates; no adverse effects were reported in either group, supporting IV-VPA as a particularly effective option in acute inpatient settings requiring rapid symptom control.

RAP-219's Phase 2 Win: A New Path for Bipolar Mania and Beyond

Rapport Therapeutics' recent announcement of positive topline Phase 2 results for RAP-219 in acute bipolar mania marks a significant milestone, not just for the company but potentially for the treatment landscape of this challenging condition. The statistically significant 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale (YMRS) at three weeks, alongside a favorable safety profile with no severe adverse events, provides compelling clinical proof-of-concept. This is particularly noteworthy given the limitations of current first-line treatments, such as valproate's potential for depressive switch at higher doses, or the known side effect profiles of lithium and quetiapine, which can include somnolence, weight gain, and tremor.

What truly sets RAP-219 apart is its novel mechanism of action as a selective negative allosteric modulator of TARP-γ8. This unique approach has now demonstrated efficacy in two distinct neurological indications, having previously shown positive Phase 2 data in drug-resistant focal epilepsy. This dual success positions RAP-219 as a highly de-risked asset with broad therapeutic potential, suggesting a 'pipeline-in-a-product' opportunity.

While the path to market is promising, with Phase 3 trials anticipated in late 2027, several considerations remain. The magnitude of RAP-219's YMRS improvement, while significant, will need to be robustly demonstrated against existing therapies in larger Phase 3 studies to establish a clear competitive advantage, especially concerning rates of symptomatic remission. Furthermore, the favorable safety profile observed over three weeks will require confirmation in longer-term trials, as chronic conditions necessitate sustained tolerability. The successful execution of these pivotal trials will be paramount for regulatory approval and to realize the full market potential of this innovative therapy.